Titlebook: Breast Cancer: Scientific and Clinical Progress; Proceedings of the B Marvin A. Rich,Jean C. Hager,Diana M. Lopez Conference proceedings 19

晚來的提名

擋泥板

冷淡一切

清唱劇

CA15-3 and Related Antigens as Serum Markers for Monitoring Breast Cancere with changes in disease status (11–13). However, the clinical use of CEA in breast cancer is limited by the specificity and sensitivity of this assay. Consequently, a number of laboratories have been involved in the develoment of more specific and sensitive serologic assays.

nutrients

Nuclear DNA Content and Prognosis in Breast Cancergnostic groups by clinical staging and histomorphological grading have been proven to be inaccurate and too subjective for prognostication in the individual patient (4–8). Therefore, new approaches for tumor grading in breast cancer have been proposed.

ANTI

Perspectives for the Clinical Use of Aromatase Inhibitorst aromatase inhibitors will find an important place in the management of breast and endometrial carcinomas and possibly benign diseases such as endometriosis, leiomyomata uteri, perimenopausal bleeding and gynecomastia.

DUCE

Repetitions

Conference proceedings 1988lly applying this knowledge to methods of detection, diagnosis and treatment: and finding ways to make these advances truly available to the public as effectively as possible. The significant progress that is occurring across this entire spectrum of pioneering investigation is reflected in these pro

Admire

Pierre Haehnel,Christian Kleitzact with MMTV have been identified in sera of 20% to 60% of patients with breast cancer (3–11). Despite the facts pointing to the existence of the relationship between MMTV and human breast cancer, contradicting results have been described (17).

幻影

Endocrine and Reproductive Systemsmbrane were discussed first, basolateral cell surface antigens and intracellular antigens were the next topics. Some studies on the prognostic value of antigen expression were presented at the end of this discussion.